Fundraising Fox
🦊/Companies
Sign in

Genomind

King of Prussia, US · Delaware corporation · 2 known investors

Find your way into Genomind

GenMedPro is a genetics-based medication management platform that analyzes 26 genes to identify drug-drug and gene-drug interactions across a patient's entire medication regimen. The platform serves healthcare providers and care teams to reduce prescribing errors, prevent adverse events, and optimize medication safety for complex polypharmacy cases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices

Founders & leadership

DR
Dr. Ronald DozoretzFounder
SHStephen Haller
Stephen HallerExecutive
GN
Gloria NussExecutive
BE
Beth E. DozoretzExecutive
THThomas Hess
Thomas HessinExecutive
MK
Michael KofflerNamed on SEC filing

Board

JCJohn Chadwick
John ChadwickinBoard directorGeneral Partner at Claritas Healthcare
TSTheresa Sexton
Theresa SextoninBoard directorGeneral Partner at Claritas Healthcare
RW
Rina WolfBoard director
JA
Joseph AntonBoard director

Investors · 2

Claritas CapitalNashville · $2M – $5M
Claritas HealthcarereportedNashville

Reported raises · per SEC filings

Form D private placements

$55.7M disclosed across 4 rounds · 2014–2020

▶$6.4MraisedApr 2021 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Beth DozoretzDirector
  • Tom HessExecutive Officer
  • Shelloy KigerDirector
  • Stephen HallerExecutive Officer
  • Theresa SextonDirector
  • John ChadwickDirector
  • Shawn Patrick O'BrienExecutive Officer, Director
Offering amount
$21.1M
Amount sold
$6.4M
First sale
Nov 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.6MraisedSep 2020 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen HallerExecutive Officer
  • Thomas HessExecutive Officer
  • Gloria NussExecutive Officer
  • Kip OlmsteadExecutive Officer
  • Brad LucasDirector
  • Shawn P. O'BrienExecutive Officer, Director
  • Theresa SextonDirector
  • John ChadwickDirector
  • Joseph AntonDirector
Offering amount
$21.7M
Amount sold
$20.6M
Minimum investment
$100K
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.8MraisedOct 2017 · 5 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Theresa SextonDirector
  • Beth E. DozoretzExecutive Officer, Director
  • Joseph AntonDirector
  • Ronald I. DozoretzExecutive Officer, Director, Promoter
  • Thomas HessExecutive Officer
  • Stephen HallerExecutive Officer
  • Rina WolfDirector
  • Gloria NussExecutive Officer
  • John ChadwickDirector
  • Michael KofflerExecutive Officer, Director, Promoter
Offering amount
$13.8M
Amount sold
$7.8M
Minimum investment
$250K
First sale
Feb 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.9MraisedJul 2016 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen HallerExecutive Officer
  • Rina WolfDirector
  • Ronald I. DozoretzExecutive Officer, Director, Promoter
  • Michael KofflerExecutive Officer, Director, Promoter
  • Gloria NussExecutive Officer
  • Beth E. DozoretzExecutive Officer, Director
  • John ChadwickDirector
  • Theresa SextonDirector
  • Joseph AntonDirector
  • Thomas HessExecutive Officer
Offering amount
$25.9M
Amount sold
$20.9M
Minimum investment
$200K
First sale
Apr 2014
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Psychcentral1068 shared keywordsPsych Central is a digital publisher providing informational content on mental health, wellness, and medical topics developed in collaboration with licensed medical professionals. The company serves general audiences seeking educational resources on health conditions and treatments.

Companies competing with Genomind for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$399.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Genomind's latest funding round brings total backing to nearly $80M - Philadelphia Business Journalbizjournals.com · Dec 2020Genomind Closes $6M Financing Round - FinSMEsfinsmes.com · Sep 2015Genomind Raises $6M in Funding Round | GenomeWebgenomeweb.com · Sep 2015Genomind Secures Series A Investment Led By Claritas Capital To Fund Growth Of Their Personalized Medicine Company - Genomindgenomind.com · Apr 2014

Frequently asked questions

What does Genomind do?
GenMedPro is a genetics-based medication management platform that analyzes 26 genes to identify drug-drug and gene-drug interactions across a patient's entire medication regimen. The platform serves healthcare providers and care teams to reduce prescribing errors, prevent adverse events, and optimize medication safety for complex polypharmacy cases.
Who founded Genomind?
Genomind was founded by Dr. Ronald Dozoretz.
Who are Genomind's investors?
Genomind's investors include Claritas Capital, Claritas Healthcare.
How much funding has Genomind raised?
Genomind has disclosed $55.7M raised across 4 rounds.
Where is Genomind headquartered?
Genomind is headquartered in King of Prussia, US.